0001209191-16-104913.txt : 20160302
0001209191-16-104913.hdr.sgml : 20160302
20160302204313
ACCESSION NUMBER: 0001209191-16-104913
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160229
FILED AS OF DATE: 20160302
DATE AS OF CHANGE: 20160302
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kaye Edward M. MD
CENTRAL INDEX KEY: 0001522780
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 161479270
MAIL ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
CITY: BOTHELL
STATE: WA
ZIP: 98011
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-02-29
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001522780
Kaye Edward M. MD
215 FIRST STREET
SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
SVP Interim CEO & CMO
Common Stock
2016-02-29
4
A
0
4704
0.00
D
109029
D
Incentive Stock Option (right to buy)
13.71
2016-02-29
4
A
0
4574
0.00
A
2026-02-28
Common Stock
4574
4574
D
Non- Qualified Stock Option (right to buy)
13.71
2016-02-29
4
A
0
95426
0.00
A
2026-02-28
Common Stock
95426
95426
D
Incentive Stock Option (right to buy)
13.71
2016-02-29
4
A
0
1389
0.00
A
2026-02-28
Common Stock
1389
1389
D
Non- Qualified Stock Option (right to buy)
13.71
2016-02-29
4
A
0
98611
0.00
A
2026-02-28
Common Stock
98611
98611
D
100% of the Restricted Stock Award granted on February 29, 2016 vests six months from the date of grant. This award is being provided in lieu of a portion of the executive's cash bonus and is subject to continued service with the Issuer.
Includes shares acquired under the Sarepta Therapeutics, Inc. 2013 Employee Stock Purchase Plan, 800 shares were acquired on February 29, 2016 at a price of $11.4665.
25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.
Half of the options begin vesting in the event the FDA provides marketing approval for eteplirsen as of the applicable PDUFA date and the other half of the options begin vesting in the event Sarepta files a Marketing Authorization Application with the EMEA prior to December 31, 2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vests immediately upon achievement of the performance condition (25% of the total Performance-Based Options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total Performance-Based Options granted) vests over four years with 25% of these remaining options vesting on the first year anniversary of the grant date and 1/48th of these remaining options vesting monthly thereafter.
/s/ David Tyronne Howton
2016-03-02